705941-45-3 Usage
General Description
(4-ACETYL-PIPERAZIN-1-YL)-ACETIC ACID is a chemical compound with the formula C10H15N3O3. It is a derivative of piperazine, a heterocyclic amine that is commonly used as a building block in pharmaceutical research and drug development. The acetyl group attached to the piperazine ring gives the compound additional chemical reactivity and potentially alters its pharmacological properties. (4-ACETYL-PIPERAZIN-1-YL)-ACETIC ACID is of interest in medicinal chemistry as it may have potential as a drug candidate or as a tool compound for studying the biological activity of piperazine derivatives. Its precise properties and potential applications would need to be further studied and characterized.
Check Digit Verification of cas no
The CAS Registry Mumber 705941-45-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,0,5,9,4 and 1 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 705941-45:
(8*7)+(7*0)+(6*5)+(5*9)+(4*4)+(3*1)+(2*4)+(1*5)=163
163 % 10 = 3
So 705941-45-3 is a valid CAS Registry Number.
InChI:InChI=1/C8H14N2O3/c1-7(11)10-4-2-9(3-5-10)6-8(12)13/h2-6H2,1H3,(H,12,13)
705941-45-3Relevant articles and documents
HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS
-
Page/Page column 148; 190; 191, (2020/06/05)
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein R1, R2, R4, R5, R6, R7, R8, R9, R10,Z, X1, X2, X3, L2, HET, n and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
NK1 and NK3 antagonists
-
Page/Page column 28, (2010/02/14)
The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-mediated conditions.
